for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Pfizer Inc.

PFE.N

Latest Trade

33.86USD

Change

0.37(+1.10%)

Volume

2,656,972

Today's Range

33.52

 - 

33.93

52 Week Range

27.89

 - 

43.02

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
33.49
Open
33.59
Volume
2,656,972
3M AVG Volume
860.64
Today's High
33.93
Today's Low
33.52
52 Week High
43.02
52 Week Low
27.89
Shares Out (MIL)
5,577.63
Market Cap (MIL)
186,794.80
Forward P/E
10.14
Dividend (Yield %)
4.66

Next Event

Pfizer Inc at Cowen Healthcare Conference (Virtual)

Latest Developments

更多

EMA Accepts Marketing Application For Somatrogon

Pfizer & Biontech Initiate A Study As Part Of Broad Development Plan To Evaluate Covid-19 Booster & New Vaccine Variants

U.S. FDA Accepts For Priority Review Pfizer’s Application For Ticovac

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Pfizer Inc.

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.

Industry

Biotechnology & Drugs

Contact Info

235 E 42ND ST

NEW YORK, NY

10017-5703

United States

+1.212.5732323

https://www.pfizer.com/

Executive Leadership

Albert Bourla

Chairman of the Board, Chief Executive Officer

John D. Young

Chief Business Officer, Group President

Frank A. D'Amelio

Chief Financial Officer, Executive Vice President - Business Operations and Global Supply

Angela Hwang

Group President, Pfizer Biopharmaceuticals Group

Dawn Rogers

Chief Human Resource Officer, Executive Vice President

Key Stats

2.59 mean rating - 22 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

53.6K

2019

51.8K

2020

41.9K

2021(E)

62.0K
EPS (USD)

2018

3.000

2019

2.950

2020

2.220

2021(E)

3.302
Price To Earnings (TTM)
26.82
Price To Sales (TTM)
4.46
Price To Book (MRQ)
2.95
Price To Cash Flow (TTM)
15.83
Total Debt To Equity (MRQ)
62.99
LT Debt To Equity (MRQ)
58.72
Return on Investment (TTM)
5.44
Return on Equity (TTM)
4.36

Latest News

Latest News

FACTBOX-Latest on the worldwide spread of the coronavirus

Johnson & Johnson's newly authorized vaccine has started shipping, while a highly transmissible variant of coronavirus first identified in the Brazilian city of Manaus has been detected in Britain for the first time.

UPDATE 1-Flowserve supplying pumps, valves for Pfizer vaccine production

Flowserve Corp, an American supplier of industrial machinery, said on Monday it was providing pumps, valves and seals to Pfizer Inc to support the production of its COVID-19 vaccine.

What you need to know about the coronavirus right now

Here's what you need to know about the coronavirus right now:

UPDATE 1-Pfizer COVID-19 vaccine reduces transmission after one dose -UK study

A single dose of Pfizer and BioNtech's COVID-19 vaccine cuts the number of asymptomatic infections and could significantly reduce the risk of transmission of the virus, results of a UK study found on Friday.

Pfizer COVID-19 vaccine reduces transmission after one dose -UK study

A single dose of the Pfizer COVID-19 vaccine developed in partnership with BioNTech could significantly reduce the risk of transmission after a single dose, results of a UK study found on Friday.

UPDATE 1-FDA allows storage, transport of Pfizer vaccine at higher temperatures

The U.S. Food and Drug Administration on Thursday approved storage and transportation of COVID-19 vaccine developed by Pfizer Inc and German partner BioNTech SE at standard freezer temperatures for up to two weeks instead of ultra-cold conditions.

FDA approves storage, transport of Pfizer-BioNTech vaccine at higher temperatures

The U.S. Food and Drug Administration on Thursday approved storage and transportation of COVID-19 vaccine developed by Pfizer Inc and German partner BioNTech SE at standard freezer temperatures for up to two weeks instead of ultra-cold conditions. (Reporting by Mrinalika...

UPDATE 1-Pfizer-BioNTech testing booster of their COVID-19 vaccine in new trial

Pfizer Inc and BioNTech SE said on Thursday they are testing a third dose of their COVID-19 vaccine to better understand the immune response against new variants of the virus.

In boost for COVID-19 battle, Pfizer vaccine found 94% effective in real world

The first big real-world study of the Pfizer/BioNTech vaccine to be independently reviewed shows the shot is highly effective at preventing COVID-19, in a potentially landmark moment for countries desperate to end lockdowns and reopen economies.

UPDATE 1-FDA to allow Pfizer-BioNTech vaccine to be stored at higher temps - NYT

The U.S. Food & Drug Administration plans to approve Pfizer Inc and BioNTech SE's request to store their COVID-19 vaccine at standard freezer temperatures instead of in ultra-cold conditions, the New York Times reported on Tuesday.

FDA to allow Pfizer-BioNTech COVID-19 vaccine to be stored at standard freezer temp: NYT

The U.S. Food & Drug Administration plans to approve Pfizer Inc and BioNTech SE's request to store their COVID-19 vaccine at standard freezer temperatures instead of in ultra-cold conditions, the New York Times reported on Tuesday.

UPDATE 2-Brazil approves Pfizer's COVID-19 shot, but has none to use

Brazil has fully approved the COVID-19 vaccine developed by Pfizer Inc and BioNTech SE , its health regulator said on Tuesday, though a dispute over a supply deal means it has none to start an immunization program with.

UPDATE 2-Pfizer to ship 13 mln COVID-19 vaccine doses per week to U.S. by mid-March, says executive

Pfizer Inc expects to deliver more than 13 million doses of its COVID-19 vaccine per week to the United States by the middle of March, more than doubling its shipments from early February, a top Pfizer executive said in prepared testimony ahead of a Tuesday congressional...

UPDATE 3-Pfizer promises to double supply as Biden pushes for quicker vaccine rollout

U.S. President Joe Biden on Friday secured a commitment from Pfizer Inc to double the COVID-19 vaccine it churns out in the coming weeks, putting his goal to fill the country's inoculation stockpile by summer in sight.

UPDATE 2-Pfizer to double weekly U.S. output of vaccine in next few weeks -CEO

Pfizer Inc Chief Executive Albert Bourla said on Friday that the drugmaker expects to be able to double the weekly number of doses of its COVID-19 vaccine it will supply to the United States in the next few weeks.

Pfizer supplied 40 million COVID vaccine doses to United States -CEO

Pfizer Inc Chief Executive Albert Bourla said on Friday that his company has supplied 40 million doses of the COVID-19 vaccine to the U.S. government. (Reporting by Alexandra Alper; Editing by Leslie Adler)

UPDATE 1-Israeli studies find Pfizer COVID-19 vaccine reduces transmission

Pfizer's COVID-19 vaccine greatly reduces virus transmission, two Israeli studies have found, shedding light on one of the biggest questions of the global effort to quash the pandemic.

Pfizer submits data showing COVID-19 vaccine's stability at higher temperatures

Pfizer Inc and partner BioNTech SE said on Friday they have submitted new data to the U.S. health regulator showing the stability of their COVID-19 vaccine at temperatures commonly found in pharmaceutical freezers and refrigerators. (Reporting by Manojna Maddipatla in Bengaluru...

Biden to visit Pfizer factory as Americans clamor for more COVID-19 vaccine supply

President Joe Biden heads to Kalamazoo, Michigan, on Friday to visit the Pfizer Inc manufacturing plant that is churning out COVID-19 vaccines, as state and local governments across the country clamor for more.

Israeli study finds Pfizer vaccine 85% effective after first shot

The first dose of Pfizer Inc's COVID-19 vaccine is 85% effective, a study of healthcare workers at an Israeli hospital has found, potentially fuelling a debate over the recommended two-dose schedule as governments try to stretch out supplies.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up